Alpha 2.0
Login Register
» Authors » Alex Kartashov

Alex Kartashov

Explore the profile of Alex Kartashov including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 28
Citations 944
Followers 0
Related Specialties
Oncology
Critical Care
Pharmacology
Top 10 Co-Authors
Derek Weycker
John Edelsberg
Rich Barron
Roland M du Bois
Gary H Lyman
Ulrich Costabel
Gerry Oster
Dominique Valeyre
Steven A Sahn
Talmadge E King Jr
Published In
Am J Respir Crit Care Med
Support Care Cancer
PLoS One
Am J Cardiovasc Drugs
J Pharm Technol
Affiliations
Soon will be listed here.
Recent Articles
1.
Effectiveness, Safety, and Costs of Thromboprophylaxis with Enoxaparin or Unfractionated Heparin Among Medical Inpatients With Chronic Obstructive Pulmonary Disease or Heart Failure
Amin A, Kartashov A, Ngai W, Steele K, Rosenthal N
J Health Econ Outcomes Res . 2024 Feb; 11(1):44-56. PMID: 38390025
Chronic obstructive pulmonary disease (COPD) and heart failure (HF) are risk factors for venous thromboembolism (VTE). Enoxaparin and unfractionated heparin (UFH) help prevent hospital-associated VTE, but few studies have compared...
2.
Trends in Patient Transfers From Overall and Caseload-Strained US Hospitals During the COVID-19 Pandemic
Sarzynski S, Mancera A, Yek C, Rosenthal N, Kartashov A, Hick J, et al.
JAMA Netw Open . 2024 Feb; 7(2):e2356174. PMID: 38358739
Importance: Transferring patients to other hospitals because of inpatient saturation or need for higher levels of care was often challenging during the early waves of the COVID-19 pandemic. Understanding how...
3.
Effectiveness, safety, and costs of thromboprophylaxis with enoxaparin or unfractionated heparin in inpatients with obesity
Amin A, Kartashov A, Ngai W, Steele K, Rosenthal N
Front Cardiovasc Med . 2023 Jul; 10:1163684. PMID: 37396589
Background: Obesity is a frequent and significant risk factor for venous thromboembolism (VTE) among hospitalized adults. Pharmacologic thromboprophylaxis can help prevent VTE, but real-world effectiveness, safety, and costs among inpatients...
4.
Treatment patterns, healthcare resource use, and costs associated with uncomplicated urinary tract infection among female patients in the United States
Moon R, Marijam A, Mitrani-Gold F, Gibbons D, Kartashov A, Rosenthal N, et al.
PLoS One . 2022 Nov; 17(11):e0277713. PMID: 36409679
Background: We evaluated associations between antibiotic prescription and healthcare resource use and costs (Part A), and between antibiotic switching and healthcare resource use, costs, and uncomplicated urinary tract infection recurrence...
5.
Retrospective Study of the Prevalence, Predictors, and Consequences of Nonadherence With Lapatinib in Women With Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab
Delea T, Kartashov A, Sharma P
J Pharm Technol . 2021 Dec; 30(1):21-30. PMID: 34860884
Lapatinib is an oral small molecule dual tyrosine kinase inhibitor that has been shown to improve time to progression versus capecitabine in women with HER2+ metastatic breast cancer (MBC) previously...
6.
Epidemiology of Invasive Escherichia coli Infection and Antibiotic Resistance Status Among Patients Treated in US Hospitals: 2009-2016
Begier E, Rosenthal N, Gurtman A, Kartashov A, Donald R, Lockhart S
Clin Infect Dis . 2021 Jan; 73(4):565-574. PMID: 33420788
Background: Published data is limited on the prevalence and risk of recurrence of extraintestinal invasive Escherichia coli infections (IEIs) in the United States. Methods: The analysis included all inpatient and...
7.
Risk factors, resource use, and cost of postoperative low cardiac output syndrome
Duncan A, Kartashov A, Robinson S, Randall D, Zhang K, Luber J, et al.
J Thorac Cardiovasc Surg . 2020 Aug; 163(5):1890-1898.e10. PMID: 32800368
Objective: Low cardiac output syndrome complicates recovery after cardiac surgery. We examined the incidence and risk factors for low cardiac output syndrome and its association with postoperative mortality, morbidity, resource...
8.
Comparative Effectiveness and Costs of Enoxaparin Monotherapy Versus Unfractionated Heparin Monotherapy in Treating Acute Coronary Syndrome
Rosenthal N, Xiao Z, Kartashov A, Levorsen A, Shah B
Am J Cardiovasc Drugs . 2020 Jun; 21(1):93-101. PMID: 32578166
Background: Enoxaparin and unfractionated heparin (UFH) are guideline-recommended anticoagulants for patients with acute coronary syndrome (ACS), including unstable angina (UA) and myocardial infarction with (STEMI) or without ST-segment elevation (NSTEMI)....
9.
Contemporary trend of acute kidney injury incidence and incremental costs among US patients undergoing percutaneous coronary procedures
Prasad A, Rosenthal N, Kartashov A, Knish K, Dreyfus J
Catheter Cardiovasc Interv . 2020 Mar; 96(6):1184-1197. PMID: 32129574
Objectives: To assess national trends of acute kidney injury (AKI) incidence, incremental costs, risk factors, and readmissions among patients undergoing coronary angiography (CAG) and/or percutaneous coronary intervention (PCI) during 2012-2017....
10.
Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice
Weycker D, Li X, Barron R, Li Y, Reiner M, Kartashov A, et al.
Support Care Cancer . 2015 Dec; 24(6):2481-90. PMID: 26670915
Purpose: Accumulating evidence suggests that not all cancer chemotherapy patients who receive first-cycle pegfilgrastim prophylaxis continue to receive it in subsequent cycles and that these patients may be subsequently at...